Clinical Trials Logo
NCT number NCT00262990
Study type Interventional
Source Novartis
Status Completed
Phase Phase 3
Start date November 2005

Clinical Trial Summary

The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.

Clinical Trial Description


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

See also
Status Clinical Trial Phase
 Recruiting NCT02891824 - ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab Phase 3
 Recruiting NCT02928549 - Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study N/A
 Recruiting NCT02855944 - ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Phase 3
 Recruiting NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
 Recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
 Not yet recruiting NCT02865811 - Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer Phase 2
 Recruiting NCT02545010 - Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer Phase 1
 Recruiting NCT02560818 - Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer N/A
 Recruiting NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
 Recruiting NCT02560337 - Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. Phase 2
 Recruiting NCT02526017 - Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
 Recruiting NCT02055690 - PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer Phase 1/Phase 2
 Recruiting NCT01690468 - PTX-200 and Carboplatin in Ovarian Cancer Phase 1/Phase 2
 Recruiting NCT02194387 - Pilot Tests to Optimize the Delivery of Energy Balance Interventions N/A
 Recruiting NCT02218502 - Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses N/A
 Recruiting NCT02321735 - DOD Long-Term Survivors of Ovarian Cancer N/A
 Recruiting NCT02017509 - Immunoscore in Rectal Cancer N/A
 Recruiting NCT02351479 - Hula, a Physical Activity Intervention for Female-Cancer Survivors N/A
 Active, not recruiting NCT01891344 - A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Phase 2
 Active, not recruiting NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1/Phase 2